Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MPO | P05164 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.66 |
| ▸ | PTPRA | P18433 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029175 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL29405769 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL128685 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL30381542 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL456668 | 1.00 | KMT2A (0.66) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11602575 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11604913 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL11602580 | 0.93 | PTPRA (0.58) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL31642414 | 0.89 | HTR2A (0.73) | KMT2AKDM4ELMNAMAPTTSHR | |
| SCHEMBL21309683 | 0.89 | HTR2A (0.73) | KMT2AKDM4ELMNAMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177537-A1 | AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF | NATIONAL TAIWAN UNIVERSITY (TW) | 2025-06-05 | — | — | US | claimed |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | BICYCLETX LIMITED (GB) | 2024-02-20 | — | — | US | claimed |
| EP-4308586-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BicycleTX Limited (GB) | 2024-01-24 | — | — | EP | claimed |
| CN-117337295-A | Bicyclic peptide ligands specific for TREM2 | 拜斯科技术开发有限公司 | 2024-01-02 | — | — | CN | claimed |
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | UNIV NEW YORK STATE RES FOUND (US) | 2023-11-16 | — | — | US | claimed |
| CN-116836959-A | Enzyme composition for synthesizing neomycin derivative and application thereof | 山东大学 | 2023-10-03 | — | — | CN | claimed |
| WO-2022195287-A9 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-10-20 | — | — | WO | claimed |
| WO-2022195287-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | WO | claimed |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BICYCLETX LIMITED (GB) | 2022-09-22 | — | — | US | claimed |
| CN-111118048-B | Use of chimeric phenylalanyl-tRNA synthetases/tRNAs | 浙江大学 | 2022-06-10 | — | — | CN | claimed |
| WO-2017220701-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-28 | — | — | WO | claimed |
| US-20170209521-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-07-27 | — | — | US | claimed |
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2011-07-28 | — | — | US | claimed |
| EP-2224961-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | The Research Foundation of the State University of New York (US) | 2010-09-08 | — | — | EP | claimed |
| WO-2009070650-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-06-04 | — | — | WO | claimed |
| US-20090030181-A1 | Peptides for Inhibiting MDM2 Function | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KP) | 2009-01-29 | — | — | US | claimed |
| WO-2005097820-A1 | PEPTIDES FOR INHIBITING MDM2 FUNCTION | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-10-20 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| EP-0421946-B1 | 3-indolepyruvic acid derivatives their method of production and therapeutic use | POLIFARMA SPA (IT) | 1996-11-20 | — | — | EP | claimed |
| US-4072691-A | Process for the resolution of DL-6-chlorotryptophan | TANABE SEIYAKU CO., LTD. (JA) | 1978-02-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183915-A1 | Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | KMT2A 3074/4885KDM4E 3034/4885LMNA 931/4885 |
| US-20170209521-A1 | SMALL MOLECULE CANCER TREATMENTS THAT CAUSE NECROSIS IN CANCER CELLS BUT DO NOT AFFECT NORMAL CELLS | HMGB2, HMGB1, HMGB3 | KMT2A 3074/4885KDM4E 3034/4885LMNA 931/4885 |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | APP, TIMCC, ADM2 | KMT2A 3481/4885KDM4E 4811/4885LMNA 1950/4885 |
| US-20220296726-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | APP, TIMCC, ADM2 | KMT2A 3481/4885KDM4E 4811/4885LMNA 1950/4885 |
| US-20230364178-A1 | Small Molecule Cancer Treatments that Cause Necrosis in Cancer Cells But Do Not Affect Normal Cells | HMGB2, HMGB1, HMGB3 | KMT2A 3074/4885KDM4E 3034/4885LMNA 931/4885 |
| US-20250177537-A1 | AN ANTIBIOTIC, METHOD OF PREPARATION AND METHOD OF TREATMENT THEREOF | BTD, CALCR, CA6 | KMT2A 1230/4885KDM4E 323/4885LMNA 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.